INNOVIVA, INC. Available-for-sale Securities
INNOVIVA, INC. (INVA) had Available-for-sale Securities of $122.71 million as of 2017-12-31, per its 10-K filed 2018-02-23.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecurities · last filed 2018-02-23
- 2017-12-31: Available-for-sale Securities $122.71M.
- 2017-09-30: Available-for-sale Securities $162.58M.
- 2017-06-30: Available-for-sale Securities $130.26M.
- 2017-03-31: Available-for-sale Securities $168.82M.
| Period end | Available-for-sale Securities |
|---|---|
| 2017-12-31 | $122.71M 10-K · filed 2018-02-23 |
| 2017-09-30 | $162.58M 10-Q · filed 2017-11-03 |
| 2017-06-30 | $130.26M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $168.82M 10-Q · filed 2017-05-05 |
| 2016-12-31 | $148.81M 10-K · filed 2018-02-23 |
| 2016-09-30 | $146.47M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $151.15M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $164.73M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $176.78M 10-K · filed 2017-02-28 |
| 2015-09-30 | $203.52M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $219.83M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $245.89M 10-Q · filed 2015-05-08 |
| 2014-12-31 | $281.64M 10-K · filed 2016-02-24 |
| 2014-09-30 | $316.74M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $346.60M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $425.47M 10-Q · filed 2014-05-07 |
| 2013-12-31 | $502.83M 10-K · filed 2015-02-27 |
| 2013-09-30 | $588.17M 10-Q · filed 2013-11-01 |
| 2012-12-31 | $335.96M 10-K · filed 2014-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |